User profiles for "author:Sherko Kuemmel"

Sherko Kümmel

Professor für Medizin, Kliniken Essen-Mitte, Wissenschaftlicher Mitarbeiter Charité Berlin
Verified email at kem-med.com
Cited by 24145

Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis

H Haller, MM Winkler, P Klose, G Dobos… - Acta …, 2017 - Taylor & Francis
Background: The aim of this meta-analysis was to systematically update the evidence for
mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy …

Hypnosis in breast cancer care: a systematic review of randomized controlled trials

H Cramer, R Lauche, A Paul… - Integrative cancer …, 2015 - journals.sagepub.com
Introduction. Many breast cancer patients and survivors experience pain and emotional
stress related to their disease, its diagnostic procedures, or treatment. Hypnosis has long …

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

D Tripathy, SA Im, M Colleoni, F Franke… - The lancet …, 2018 - thelancet.com
Background In MONALEESA-2, ribociclib plus letrozole showed improved progression-free
survival compared with letrozole alone as first-line treatment for postmenopausal patients …

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their …

E De Azambuja, AP Holmes, M Piccart-Gebhart… - The lancet …, 2014 - thelancet.com
Background Findings from the randomised phase 3 NeoALTTO trial in women with HER2-
positive early breast cancer showed that the combination of lapatinib and trastuzumab …

West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by …

O Gluz, UA Nitz, M Christgen, RE Kates… - Journal of Clinical …, 2016 - ascopubs.org
Purpose The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool
in early hormone receptor–positive breast cancer (BC); however, only a few prospective …

[PDF][PDF] Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2 …

YS Lu, SA Im, M Colleoni, F Franke, A Bardia… - Clinical Cancer …, 2022 - AACR
Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant
progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 …

A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients

S Kuemmel, J Heil, A Rueland, C Seiberling… - Annals of …, 2022 - journals.lww.com
Objective: This study aimed to investigate the feasibility and accuracy of non-radioactive
TLN biopsy and TAD in routine clinical practice. Background Data: TAD involves TLN biopsy …

[HTML][HTML] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective …

U Nitz, O Gluz, M Christgen, RE Kates… - Breast cancer research …, 2017 - Springer
Abstract Background The prospective phase 3 PlanB trial used the Oncotype DX®
Recurrence Score®(RS) to define a genomically low-risk subset of clinically high-risk pN0-1 …

[HTML][HTML] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …

X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - Annals of oncology, 2014 - Elsevier
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …

Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging

TA Heusner, S Kuemmel, A Koeninger… - European journal of …, 2010 - Springer
Purpose The aim of the study was to prospectively compare the diagnostic value of whole-
body diffusion-weighted imaging (DWI) and FDG PET/CT for breast cancer (BC) staging …